Health Care's Sweet 16 Stocks: Gilead vs. Amgen
Mar 31st 2013 1:00PM
Updated Mar 31st 2013 1:06PM
Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Florida Gulf Coast have busted brackets of would-be basketball prognosticators.
Here at The Motley Fool, we decided to stick with what we know, trading our basketball picks in for stock picks. We formed our own Sweet 16 filled with the top Big Pharma and Big Biotech stocks in a winner-take-all tournament is determined by the collective intelligence of our CAPS community.
This matchup is a heavyweight bout between Gilead and Amgen. Watch and find out which stock gets eliminated and which will advance to the next round.
What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
The article Health Care's Sweet 16 Stocks: Gilead vs. Amgen originally appeared on Fool.com.Brenton Flynn and David Williamson have no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.